Industry-Expert Theaters
Expo Hall, #1967 and #2467

Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

  Saturday, March 16
  Saturday, March 16

10:15 a.m. – 11:15 a.m.

Empowering the Transformation of Heart Failure
Theater 1, Expo Hall, #1967
Sponsored by Abbott

Heart failure is a challenging and complex clinical syndrome that is difficult to manage and significantly reduces quality of life for patients. In this program, heart failure management experts will discuss treatment options available across the disease continuum. Through case studies, you will learn how the early identification of heart failure decompensation, and timely referral to advanced therapies, can optimize patient outcomes and improve functional capacity.

Introduction – Tom Heywood, MD

Challenges in Managing the Heart Failure Patient – Gregg Fonarow, MD

Patient Case Studies: Heart Failure Therapy Solutions Across the Heart Failure Patient Continuum

  • The CRT Patient – Ulrika Birgersdotter-Green, MD
  • The CMEMS Patient – Tom Heywood, MD
  • The LVAD Patient – Nir Uriel, MD

Moderator:
Tom Heywood, MD, FACC; Medical Director, Scripps Advanced Heart Failure and Mechanical Circulatory Support Program, Scripps Clinic

Speakers:
Ulrika Birgersdotter-Green, MD, FHRS; Director Pacemaker and ICD Services, Professor of Medicine & Board Certified Cardiologist, University of California San Diego School of Medicine

Gregg Fonarow, MD, FACC, FAHA, FHFSA; Director, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center

Nir Uriel, MD; Director, Heart Failure, Transplant and Mechanical Circulatory Support, Louis Bloack Professor of Medicine, University of Chicago

Lower Together: LDL-C, Risk, Hassle, Cost
Theater 2, Expo Hall, #2467
Sponsored by Amgen

Join Dr. Michael Davidson for an educational presentation on the treatment of very high risk patients described in the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Hear about his experience and the treatment options available for appropriate patients.

Speaker:

Michael Davidson, MD

12:45 p.m. – 1:45 p.m.

Improving Outcomes for Hospitalized Patients with HFrEF: Looking Beyond Stabilization
Theater 1, Expo Hall, #1967
Speakers to be announced
Sponsored by Novartis Pharmaceuticals Corporation

Get the Diagnosis Right: Identifying Amyloidosis in Your Patients
Theater 2, Expo Hall, #2467
Sponsored by Alnylam Pharmaceuticals

Please join our expert faculty panel during this Industry Expert Theater to learn about the different types of amyloidosis, with a focus on transthyretin-mediated (ATTR) amyloidosis. We will discuss the importance of suspecting the disease in your patients, which can manifest in a multisystem manner, and the potential misdiagnoses due to the varying presentations. Additionally, we will explore tools and techniques that can be used to recognize ATTR amyloidosis. We hope you attend to learn about the importance of early identification and diagnosis of your patients.

Speaker Chair:
Mathew S Maurer, MD; New York, NY

Speakers:
Jose Nativi-Nicolau, MD; Salt Lake City, UT

Ronald Witteles, MD; Stanford, CA

3:45 p.m. – 4:45 p.m.

Reversal of Novel Oral Anticoagulants in Patients Experiencing Life Threatening Bleeds: Review of Clinical Evidence and Practice Recommendations for Patient Management
Theater 1, Expo Hall, #1967
Speakers to be announced
Sponsored by Portola Pharmaceuticals

Jardiance® (empagliflozin) Tablets: Data From the Comprehensive Clinical Development Program
Theater 2, Expo Hall, #2467
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA

This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE.

Attendees will also have the opportunity to ask the faculty questions about the data presented.

Speaker: James O'Keefe, MD; Director of Cardio Wellness Center, Saint Luke's of Kansas City, Professor of Medicine, University of Missouri-Kansas City, Kansas City, MO

  Sunday, March 17
  Sunday, March 17

9:45 a.m. – 10:45 a.m.

A Hospitalization for Heart Failure: A Bad Omen or an Opportunity?
Theater 1, Expo Hall, #1967
Sponsored by Novartis Pharmaceuticals Corporation

The clinical course of heart failure often involves periods of acute decompensation that can lead to hospitalization, with one study showing that more than 80% of newly diagnosed patients experience at least one hospitalization within a mean follow-up of 4.7 years. Rates of readmission and mortality are high in the 30 days following discharge, and repeat hospitalizations are associated with poor prognosis and diminished quality of life (QoL). Guidelines recommend measurement of natriuretic peptides (BNP and NT-proBNP) at admission and discharge to establish prognosis. Achieving target levels of natriuretic peptides and implementing guideline-directed medical therapies during hospitalization improves survival and reduces risk of rehospitalization. This program will discuss the impact of hospitalization on outcomes and QoL, emphasize repeat hospitalizations as a sign of disease progression, and highlight the importance of optimizing therapy during hospitalization.

Speakers:
Robert J. Mentz, MD, FACC, FAHA, FHFSA; Associate Professor of Medicine, Director, Duke Cooperative Cardiovascular Society, Associate Program Director, Cardiovascular Disease Fellowship, Duke University Medical Center / Duke Clinical Research Institute, Durham, NC

Susan M. Joseph, MD; Medical Director, Mechanical Circulatory Support, Advanced Heart Failure and Transplant Cardiologist, Baylor University Medical Center, Dallas TX

Who Are The Highest Risk CV Patients & How Do We Manage Them? A Focus on Post-MI and PAD
Theater 2, Expo Hall, #2467
Sponsored by Amgen

Join Dr. Allen J. Taylor for a disease state educational program on identifying and managing the highest risk CV patients, with a focus on Post-MI and PAD patients.

Speaker:
Dr. Allen J. Taylor

12:45 p.m. – 1:45 p.m.

Session title to be announced
Theater 1, Expo Hall, #1967
Speakers to be announced
Sponsored by Akcea Therapeutics

Lower Together: LDL-C, Risk, Hassle, Cost
Theater 2, Expo Hall, #2467
Sponsored by Amgen

Join Dr. Benjamin Ansell for an educational presentation on the treatment of very high risk patients described in the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Hear about his experience and the treatment options available for appropriate patients.

Speaker:

Dr. Benjamin Ansell

3:45 p.m. – 4:45 p.m.

Topic: Heart Failure
Theater 1, Expo Hall, #1967
Speakers to be announced
Sponsored by Novartis Pharmaceuticals Corporation

Understanding the Spectrum of LDL-C in CV Disease: A Focus on Low LDL
Theater 2, Expo Hall, #2467
Sponsored by Amgen

Join Dr. James Underberg for a disease state educational program that will focus on the criticality of lowering LDL-C in patients and physiology of very low LDL-C levels.

Speaker:
Dr. James A. Underberg

  Monday, March 18
  Monday, March 18

9:45 a.m. – 10:45 a.m.

Transforming Patient Care Delivery with High-Sensitivity Troponin I
Theater 1, Expo Hall, #1967
Sponsored by Siemens Healthineers

High-sensitivity cardiac troponin assays can facilitate earlier diagnosis of acute myocardial infarction. The latest HIGH-US clinical trial data documenting the performance of the Atellica® IM High-Sensitivity Troponin I Assay (TnIH) will be presented. Additionally, the keys to a successful high-sensitivity troponin implementation and how high-sensitivity troponin positively impacts clinical decision pathways will also be presented.

Speakers:

Christopher deFilippi, MD; Vice Chair of Academic Affairs, Inova Heart and Vascular Institute, Inova Heart and Vascular Institute, Baltimore, MD

Alan Wu, Ph.D, DABCC, FACB; Chief, Clinical Chemistry and Toxicology Laboratories, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco CA

Exploring A1C and Cardiovascular Safety Data in T2D Therapies
Theater 2, Expo Hall, #2467
Sponsored by Novo Nordisk

Speaker:

Robert Chilton, DO, FACC, FAHA, FACOI; Professor of Medicine, Director of Catheterization Lab, Director Clinical Proteomics, University of Texas Health Science Center, San Antonio Texas

11:30 a.m. – 12:30 p.m.

Session title to be announced
Theater 1, Expo Hall, #1967
Speakers to be announced
Sponsored by ZOLL

Reduce Cardiovascular Risk With VASCEPA® (icosapent ethyl): Evidence From REDUCE-IT™
Theater 2, Expo Hall, #2467
Speakers to be announced
Sponsored by Amarin Pharma Inc

Despite the benefits of LDL-C lowering, many patients on statin therapy with elevated triglycerides remain at risk for cardiovascular disease. The unprecedented data from the VASCEPA® cardiovascular outcomes trial, REDUCE-IT™, and its potential impact on patient care will be evaluated in this presentation. In addition, the unique mechanisms of action and safety of single-agent, EPA-only VASCEPA will be reviewed. Join the experts at this program to discuss how to Reduce Cardiovascular Risk With VASCEPA® (icosapent ethyl): Evidence From REDUCE-IT™.

Visit the Amarin booth #2239 for more information.

Financial support for this program is provided by Amarin Pharma, Inc.

Speakers:

Matthew J. Budoff, MD; Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

R. Preston Mason, PhD; Brigham & Women's Hospital, Harvard Medical School, President, Elucida Research, Boston, MA


Schedule is current as of Feb. 6, 2019, and is subject to change. Please check back for updates.

*Industry-Expert Theater presentations are not part of ACC.19, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

ADVERTISEMENT
ACC Logo
ACC.19 on Social Media:
      
2018 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us